Elsevier

Heart Rhythm

Volume 17, Issue 9, September 2020, Pages 1456-1462
Heart Rhythm

Contemporary Review
SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes

https://doi.org/10.1016/j.hrthm.2020.03.024Get rights and content

Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) has become a serious threat to public health globally in short time. At this point in time, there is no proven effective therapy. The interactions with concomitant disease are largely unknown, and that may be particularly pertinent to inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19–related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19–associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic.

Keywords

Brugada syndrome
Catecholaminergic polymorphic ventricular tachycardia
COVID-19
Long QT syndrome
SARS-CoV-2
Short QT syndrome

Cited by (0)

1

European Cardiac Arrhythmia Genetics Focus Group of European Heart Rhythm Association.

View Abstract